StocksFundsScreenerSectorsWatchlists
ZBH

ZBH - Zimmer Biomet Holdings Inc Stock Price, Fair Value and News

124.48USD-3.04 (-2.38%)Market Closed

Market Summary

ZBH
USD124.48-3.04
Market Closed
-2.38%

ZBH Alerts

  • 1 major insider sales recently.

ZBH Stock Price

View Fullscreen

ZBH RSI Chart

ZBH Valuation

Market Cap

25.5B

Price/Earnings (Trailing)

24.93

Price/Sales (Trailing)

3.45

EV/EBITDA

16.49

Price/Free Cashflow

19.78

ZBH Price/Sales (Trailing)

ZBH Profitability

EBT Margin

14.43%

Return on Equity

8.2%

Return on Assets

4.76%

Free Cashflow Yield

5.06%

ZBH Fundamentals

ZBH Revenue

Revenue (TTM)

7.4B

Rev. Growth (Yr)

6.3%

Rev. Growth (Qtr)

10.63%

ZBH Earnings

Earnings (TTM)

1.0B

Earnings Growth (Yr)

421.23%

Earnings Growth (Qtr)

157.65%

Breaking Down ZBH Revenue

Last 7 days

-2.2%

Last 30 days

-1.7%

Last 90 days

1.1%

Trailing 12 Months

-6.1%

How does ZBH drawdown profile look like?

ZBH Financial Health

Current Ratio

1.61

Debt/Equity

0.39

Debt/Cashflow

0.32

ZBH Investor Care

Dividend Yield

0.77%

Dividend/Share (TTM)

0.96

Buy Backs (1Y)

1.86%

Diluted EPS (TTM)

4.88

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20237.1B7.2B7.3B7.4B
20226.9B6.9B6.9B6.9B
20216.8B7.4B7.1B6.8B
20207.8B7.0B7.1B7.0B
20197.9B7.9B7.9B8.0B
20187.8B7.9B7.9B7.9B
20177.8B7.8B7.7B7.8B
20166.8B7.5B7.6B7.7B
20154.6B4.6B5.3B6.0B
20144.6B4.7B4.7B4.7B
20134.5B4.5B4.6B4.6B
20124.5B4.5B4.5B4.5B
20114.3B4.4B4.4B4.5B
20104.2B4.2B4.2B4.2B
20094.1B4.0B4.0B4.1B
200804.0B4.0B4.1B
20070003.9B

Tracking the Latest Insider Buys and Sells of Zimmer Biomet Holdings Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 01, 2024
winkler lori
acquired
-
-
772
svp and chro
Apr 01, 2024
winkler lori
sold (taxes)
-28,089
130
-215
svp and chro
Mar 07, 2024
yi sang
sold
-216,296
126
-1,705
group president, asia pacific
Mar 07, 2024
yi sang
acquired
156,059
91.53
1,705
group president, asia pacific
Mar 06, 2024
ellingson rachel
sold (taxes)
-55,989
125
-445
svp & chief strategy officer
Mar 06, 2024
upadhyay suketu
sold (taxes)
-241,449
125
-1,919
exec. vp, cfo
Mar 06, 2024
upadhyay suketu
acquired
-
-
4,561
exec. vp, cfo
Mar 06, 2024
phipps chad f
sold (taxes)
-103,802
125
-825
sr. vp/gen counsel/secretary
Mar 06, 2024
yi sang
acquired
-
-
2,365
group president, asia pacific
Mar 06, 2024
stellato paul a
acquired
-
-
609
vp, controller & cao

1–10 of 50

Which funds bought or sold ZBH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 11, 2024
Radnor Capital Management, LLC
reduced
-2.74
16,000
309,000
0.05%
Apr 11, 2024
Pflug Koory, LLC
unchanged
-
44,852
575,829
0.28%
Apr 11, 2024
SALEM INVESTMENT COUNSELORS INC
added
2.06
8,210
84,999
-%
Apr 11, 2024
Boston Common Asset Management, LLC
reduced
-37.01
-3,778,000
8,141,000
0.20%
Apr 11, 2024
MEYER HANDELMAN CO
reduced
-4.87
219,467
7,161,240
0.25%
Apr 11, 2024
OPTIMUM INVESTMENT ADVISORS
unchanged
-
5,654
72,589
0.03%
Apr 11, 2024
MARYLAND CAPITAL ADVISORS INC.
unchanged
-
412
5,280
-%
Apr 11, 2024
Gulf International Bank (UK) Ltd
unchanged
-
185,000
2,373,000
0.06%
Apr 11, 2024
City State Bank
reduced
-2.54
14,000
254,000
0.11%
Apr 11, 2024
Bridge Creek Capital Management LLC
added
1.63
309,372
3,339,090
1.07%

1–10 of 50

Are Funds Buying or Selling ZBH?

Are funds buying ZBH calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ZBH
No. of Funds

Unveiling Zimmer Biomet Holdings Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
price t rowe associates inc /md/
4.5%
9,426,866
SC 13G
Feb 13, 2024
dodge & cox
5.5%
11,474,535
SC 13G
Feb 13, 2024
vanguard group inc
11.42%
23,858,865
SC 13G/A
Jan 25, 2024
blackrock inc.
9.0%
18,704,377
SC 13G/A
Feb 14, 2023
price t rowe associates inc /md/
5.3%
11,200,109
SC 13G
Feb 09, 2023
vanguard group inc
11.46%
24,055,739
SC 13G/A
Jan 30, 2023
blackrock inc.
10.4%
21,803,709
SC 13G/A
Jan 24, 2023
blackrock inc.
10.4%
21,803,709
SC 13G/A
Nov 07, 2022
jpmorgan chase & co
2.4%
5,091,869
SC 13G/A
Apr 08, 2022
vanguard group inc
11.04%
23,102,761
SC 13G/A

Recent SEC filings of Zimmer Biomet Holdings Inc

View All Filings
Date Filed Form Type Document
Apr 03, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading

Peers (Alternatives to Zimmer Biomet Holdings Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
189.3B
40.1B
-9.21% 5.29%
33.08
4.72
-8.12% -17.45%
67.9B
19.5B
-1.55% -8.27%
54.08
3.48
4.02% -22.04%
23.7B
3.9B
-1.72% -7.67%
53.19
6.13
3.42% 23.09%
20.5B
14.8B
-5.55% -6.65%
7.71
1.38
2.12% 209.17%
MID-CAP
9.1B
12.3B
-5.72% -13.98%
21.94
0.74
-2.44% -22.68%
9.1B
3.5B
-2.81% 14.53%
31.84
2.6
4.97% 18.89%
8.8B
2.7B
-10.75% -38.18%
-13.76
3.28
-4.68% 82.43%
6.5B
4.0B
-8.29% -23.99%
-48.26
1.64
1.10% 85.84%
3.4B
366.4M
-0.38% 19.00%
-568.11
9.41
33.86% 89.83%
2.3B
6.6B
-5.95% -4.86%
11.79
0.35
2.78% -0.87%
SMALL-CAP
1.3B
3.2B
-4.92% -19.00%
-1.93
0.41
7.73% -1066.14%
371.2M
166.7M
-1.34% -7.94%
-4.49
2.23
6.67% -456.34%
255.1M
324.0M
14.75% -32.34%
-1.33
0.79
-3.19% -337.41%
49.2M
52.3M
-18.86% -53.44%
-2.63
0.94
17.61% 19.28%
4.0M
3.7M
-9.04% 297.37%
-0.32
1.06
5.77% 8.23%

Zimmer Biomet Holdings Inc News

Latest updates
Defense World47 minutes ago
Yahoo Movies Canada12 Apr 202408:03 am
Yahoo Finance10 Apr 202401:40 pm

Zimmer Biomet Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue10.6%1,9401,7541,8701,8311,8251,6701,7821,6631,7771,6851,7631,6012,0851,9291,2261,7842,1261,8921,9891,9762,071
Costs and Expenses6.7%1,5861,4871,5401,5041,8531,4251,5011,4651,6431,4421,5391,3437771,6301,3982,2407931,6471,7841,6252,862
  S&GA Expenses7.0%722675726716727655695685805684697657429790665829349826839796999
EBITDA Margin23.1%0.25*0.20*0.20*0.19*0.17*0.17*0.17*0.16*0.18*0.22*0.22*0.19*---------
Interest Expenses1.6%-50.30-51.10-51.60-48.20-42.60-42.30-38.80-41.10-48.80-52.60-54.70-52.30-53.20-54.00-54.00-50.90-52.50-56.80-59.70-58.00-68.50
Income Taxes-339.7%-13556.0067.0054.0055.00-16.6046.0028.00-29.2028.0033.0021.00-97.2010.00-13.705.00-44.50-2478.0046.0037.00
Earnings Before Taxes29.8%285219277287-74.80178200101-83.90191178214365256-221-503264185140292-865
EBT Margin48.4%0.14*0.10*0.09*0.08*0.06*0.06*0.06*0.06*0.07*0.13*0.14*0.09*---------
Net Income157.7%419163210233-13019415414.00-84.00146142198334243-206-508321431134246-901
Net Income Margin112.5%0.14*0.07*0.07*0.06*0.03*0.04*0.03*0.03*0.06*0.11*0.12*0.08*---------
Free Cashflow107.5%526253251261181404305279288380394198---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets1.3%21,49721,21721,29421,24421,06621,33321,45321,61823,45624,00924,22324,02724,41824,02623,64825,51324,63924,31524,20624,28924,127
  Current Assets5.4%4,6104,3724,3884,4124,4274,5344,4634,5174,8855,3125,3575,0005,0835,1534,7076,3714,7244,4024,3914,4994,427
    Cash Equivalents42.3%4162923203303765453864363789201,0427247759677132,434618513403587543
  Inventory2.7%2,3852,3232,2762,2412,1472,1292,1232,1322,1482,5172,5332,5122,1742,4922,4972,4632,3852,3622,3452,3102,257
  Net PPE1.4%2,0602,0321,9751,9061,8731,8021,7971,8261,8372,0082,0052,0221,8642,0432,0572,0662,0772,0552,0362,0142,015
  Goodwill1.2%8,8198,7108,7448,7358,5808,7998,8698,8968,9199,2129,2489,2338,9839,0398,9828,9519,1979,5459,5949,5709,594
Liabilities3.6%9,0098,6998,9169,0869,0399,0829,3289,59610,79011,29411,64011,57712,21812,14712,00413,63012,24612,23012,54412,75012,851
  Current Liabilities37.9%2,8572,0722,2342,3362,3582,2962,4642,6743,4682,9392,9292,0892,5572,2662,1613,7803,4423,7743,6782,2552,421
  Long Term Debt-5.1%4,8685,1275,1895,2055,1525,0555,1725,2865,4646,4586,8037,5397,6277,8407,7597,7246,7216,3466,7198,3118,414
    LT Debt, Current153.5%9003555205855446598521,0151,6051,0461,0503005004504501,9501,5002,0002,000500525
    LT Debt, Non Current-5.1%4,8685,1275,1895,2055,1525,0555,1725,2865,4646,4586,8037,5397,6277,8407,7597,7246,7216,3466,7198,3118,414
Shareholder's Equity-0.2%12,48112,51112,37912,15812,02012,25112,12512,02112,66612,71412,58312,45012,19911,87811,64411,88312,39312,08611,66211,53911,276
  Retained Earnings3.7%10,38510,0159,9029,7429,5599,7409,6079,50310,29210,42610,33110,23810,0879,8039,6109,86610,42710,1559,7739,6889,491
  Additional Paid-In Capital0.5%9,8469,8019,7669,6929,5049,4649,4199,3869,3159,2959,2499,1999,1229,0739,0148,9848,9208,8678,7778,7488,686
Shares Outstanding-0.1%209209209209210210209209209209209208---------
Minority Interest6.9%8.007.007.007.007.006.006.006.006.006.005.005.005.006.003.004.005.004.003.005.005.00
Float---30,367---22,003---33,533,707,317---24,675,479,718---24,106--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations74.3%588338348308244451346316338424419224296381-52.80451227578301284380
  Share Based Compensation62.2%25.0016.0034.0025.0027.0027.0028.0023.0015.0019.0022.0020.0012.0024.0022.0017.0016.0022.0020.0020.0020.00
Cashflow From Investing-33.3%-220-165-243-149-112-85.20-243-81.10-124-112-98.90-108-266-91.40-85.30-121-53.40-163-322-105-82.40
Cashflow From Financing-28.3%-251-196-109-206-313-193-146-122-655-426-28.30-195-284-42.60-1,5851,493-180-298-163-135-275
  Dividend Payments0.2%50.0050.0050.0050.0050.0050.0050.0050.0050.0050.0050.0050.0050.0050.0050.0050.0049.0049.0049.0049.0049.00
  Buy Backs-410-14.00268-----------------

ZBH Income Statement

2023-12-31
Consolidated Statements of Earnings - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Net Sales$ 7,394.2$ 6,939.9$ 6,827.3
Type of Revenue [Extensible List]us-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMember
Cost of products sold, excluding intangible asset amortization$ 2,083.8$ 2,019.5$ 1,960.4
Type of Cost, Good or Service [Extensible List]us-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMember
Intangible asset amortization$ 561.5$ 526.8$ 529.5
Research and development458.7406.0435.8
Selling, general and administrative2,838.92,761.72,843.4
Goodwill and intangible asset impairment 292.816.3
Restructuring and other cost reduction initiatives151.9191.6125.7
Quality remediation 33.852.8
Acquisition, integration, divestiture and related21.711.43.1
Operating expenses6,116.56,243.65,967.0
Operating Profit1,277.7696.3860.3
Other (expense) income, net(9.3)(128.0)12.2
Interest expense, net(201.2)(164.8)(208.4)
Loss on early extinguishment of debt  (165.1)
Earnings from continuing operations before income taxes1,067.3403.5499.0
Provision for income taxes from continuing operations42.2112.353.5
Net Earnings from Continuing Operations1,025.1291.2445.5
Less: Net earnings attributable to noncontrolling interest1.11.00.5
Net Earnings from Continuing Operations of Zimmer Biomet Holdings, Inc.1,024.0290.2445.0
Loss from Discontinued Operations, Net of Tax (58.8)(43.4)
Net Earnings of Zimmer Biomet Holdings, Inc.$ 1,024.0$ 231.4$ 401.6
Basic Earnings Per Common Share   
Earnings from Continuing Operations$ 4.91$ 1.38$ 2.14
Loss from Discontinued Operations (0.28)(0.21)
Basic Earnings Per Common Share4.911.11.93
Diluted Earnings Per Common Share   
Earnings from Continuing Operations4.881.382.12
Loss from Discontinued Operations (0.28)(0.21)
Diluted Earnings Per Common Share$ 4.88$ 1.1$ 1.91
Weighted Average Common Shares Outstanding   
Basic208.7209.6208.6
Diluted209.7210.3210.4

ZBH Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Current Assets:  
Cash and cash equivalents$ 415.8$ 375.7
Accounts receivable, less allowance for credit losses1,442.41,381.5
Inventories2,385.22,147.2
Prepaid expenses and other current assets366.1522.9
Total Current Assets4,609.54,427.3
Property, plant and equipment, net2,060.41,872.5
Goodwill8,818.58,580.2
Intangible assets, net4,856.45,063.8
Other assets1,152.11,122.2
Total Assets21,496.921,066.0
Current Liabilities:  
Accounts payable410.6354.1
Income taxes payable61.238.5
Other current liabilities1,485.71,421.3
Current portion of long-term debt900.0544.3
Total Current Liabilities2,857.42,358.2
Deferred income taxes, net357.6474.8
Long-term income tax payable273.7421.2
Other long-term liabilities652.1632.6
Long-term debt4,867.95,152.2
Total Liabilities9,008.79,039.0
Commitments and Contingencies (Note 21)
Stockholders' Equity:  
Common stock, $0.01 par value, one billion shares authorized, 316.2 million (313.8 million in 2022) issued3.23.1
Paid-in capital9,846.19,504.4
Retained earnings10,384.59,559.3
Accumulated other comprehensive loss(191.0)(179.3)
Treasury stock, 110.6 million shares (104.8 million shares in 2022)(7,562.3)(6,867.2)
Total Zimmer Biomet Holdings, Inc. stockholders' equity12,480.512,020.3
Noncontrolling interest7.76.7
Total Stockholders' Equity12,488.112,027.0
Total Liabilities and Stockholders' Equity$ 21,496.9$ 21,066.0
ZBH
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
 CEO
 WEBSITEzimmerbiomet.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES18000

Zimmer Biomet Holdings Inc Frequently Asked Questions


What is the ticker symbol for Zimmer Biomet Holdings Inc? What does ZBH stand for in stocks?

ZBH is the stock ticker symbol of Zimmer Biomet Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Zimmer Biomet Holdings Inc (ZBH)?

As of Fri Apr 12 2024, market cap of Zimmer Biomet Holdings Inc is 25.53 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ZBH stock?

You can check ZBH's fair value in chart for subscribers.

What is the fair value of ZBH stock?

You can check ZBH's fair value in chart for subscribers. The fair value of Zimmer Biomet Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Zimmer Biomet Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ZBH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Zimmer Biomet Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether ZBH is over valued or under valued. Whether Zimmer Biomet Holdings Inc is cheap or expensive depends on the assumptions which impact Zimmer Biomet Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ZBH.

What is Zimmer Biomet Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 12 2024, ZBH's PE ratio (Price to Earnings) is 24.93 and Price to Sales (PS) ratio is 3.45. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ZBH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Zimmer Biomet Holdings Inc's stock?

In the past 10 years, Zimmer Biomet Holdings Inc has provided 0.039 (multiply by 100 for percentage) rate of return.